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Abstract: This study aimed to analyze the treatment and outcomes of older glioblastoma 
patients. Forty-four patients older than 70 years of age were referred to the Paul Strauss 
Center for chemotherapy and radiotherapy. The median age was 75.5 years old (range: 70–84), 
and the patients included 18 females and 26 males. The median Karnofsky index (KI) was 
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70%. The Charlson indices varied from 4 to 6. All of the patients underwent surgery.  
O6-methylguanine–DNA methyltransferase (MGMT) methylation status was determined in 
25 patients. All of the patients received radiation therapy. Thirty-eight patients adhered to a 
hypofractionated radiation therapy schedule and six patients to a normofractionated schedule. 
Neoadjuvant, concomitant and adjuvant chemotherapy regimens were administered to 12, 35 
and 20 patients, respectively. At the time of this analysis, 41 patients had died. The median 
time to relapse was 6.7 months. Twenty-nine patients relapsed, and 10 patients received 
chemotherapy upon relapse. The median overall survival (OS) was 7.2 months and the one- 
and two-year OS rates were 32% and 12%, respectively. In a multivariate analysis, only the 
Karnofsky index was a prognostic factor. Hypofractionated radiotherapy and chemotherapy 
with temozolomide are feasible and acceptably tolerated in older patients. However, 
relevant prognostic factors are needed to optimize treatment proposals. 
Keywords: hypofractionated radiotherapy; chemotherapy; elderly 
 
1. Introduction 
Glioblastoma (GBM) is among the most aggressive tumor types. Its prognosis is associated with a 
rapidly progressive disease course and a generally fatal outcome. According to the literature, half of all 
patients diagnosed with glioblastoma are older than 65 years of age. In this population, establishing a 
standard of care with which to prolong survival without degrading the patient’s quality of life remains 
very challenging. 
Since older patients are often excluded from clinical trials, elderly patients are at risk of receiving 
inadequate treatment, which could explain the poor outcomes of these patients. Currently, radiation 
therapy (RT) is recognized to improve survival in elderly patients with malignant gliomas when 
compared to the administration of only best supportive care [1]. Furthermore, the randomized data do 
not demonstrate a benefit for the standard 6-week course of RT over a hypofractionated course of RT, 
given over 2 or 3 weeks [2,3]. Other treatments such as chemotherapy alone have been favorably 
compared with radiotherapy alone [3–5]. 
The use of concurrent and adjuvant chemotherapy is associated with improvements in patients older 
than 60 or 65 years of age [6]. However, this treatment modality has been suspected to associate with 
additional toxicity in older patients, compared to younger patients [7]. A recent retrospective study 
suggested that no benefit was obtained from the addition of concurrent temozolomide (TMZ), but that 
a sequential strategy could be more efficient [8]. Therapeutic decisions are increasingly influenced by 
prognostic factors such as molecular biology [9,10], but such factors do not help physicians to select 
the best therapeutic option. 
We retrospectively analyzed the outcomes of a monocentric elderly population of GBM patients who 
were treated with hypofractionated radiation in combination or not with concurrent and adjuvant TMZ. 
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2. Patients and Methods 
From 09/2005 to 01/2010, 44 patients older than 70 years have been referred to the radiotherapy 
and oncology departments at the Paul Strauss Center.  
3. Treatments 
All patients underwent surgery. For irradiation, all patients were immobilized with custom 
thermoplastic masks. Dedicated CT-scans and MRI were performed a maximum of 10 days before 
initiating irradiation. We did not use preoperative MRI. For all patients, target volume delineation was 
performed on T1-weighted MRI that had been matched and fused with a CT scan. The gross tumor 
volume (GTV) was defined as the operative bed plus the contrast enhancement area in the T1-weighted 
MRI sequence. The clinical target volume (CTV) was designated by the addition of a geometric 2-cm 
margin that was corrected to the anatomical borders. The planning target volume (PTV) was defined as 
the CTV plus a 3-mm margin.  
Twelve patients received chemotherapy with carmustine wafers and/or temozolomide before 
radiotherapy. Concomitant chemotherapy was administered to 35 patients, 34 of whom received daily 
temozolomide at a dose of 75 mg/m
2
 and one who received temozolomide and cilengitide according to 
a trial protocol. Nine patients did not receive any concomitant chemotherapy because of their general 
conditions. Of those patients who received concomitant chemotherapy, twenty received adjuvant 
chemotherapy with a 5-day temozolomide schedule. The temozolomide dose ranged from 150–200 mg/m2 
per day and was given on five consecutive days per month for a total of at least six months if the 
patients did not develop complications. 
4. Follow-Up 
On follow-up imaging, tumor progression was defined according to the Macdonald criteria [11]. 
Individuals who presented with interval clinical deterioration suggestive of tumor progression 
underwent new, earlier imaging to confirm the diagnoses. At the time of confirmed tumor progression, 
the patients were treated at the discretion of the referent neuro-oncologist, and the types of 
administered second-line therapy were recorded. 
5. Statistical Analysis 
Statistics 
The data recorded and included in the analysis were the patient’s age at diagnosis, gender, 
symptoms prior to diagnosis, symptom duration prior to diagnosis, date and extent of surgery (biopsy, 
partial or complete resection), MGMT status, pre-radiotherapy steroid requirement, Karnofsky 
Performance Status before surgery, medical history, tumor site and lateralization. The recorded 
treatment variables were the type of radiotherapy, radiotherapy parameters, use of a delay between 
surgery and radiotherapy, use of concomitant and adjuvant chemotherapy, use of antiepileptic drugs, 
date of radiographic progression, salvage treatment for progression, and date of last known status with 
the cause of death. MGMT status was determined by the percentage of methylated DNA in a  
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tumor sample (unmethylated if <5%, minor if 5%–30%, methylated if >30% methylated,).  
Surgery-radiotherapy delays were used to define different groups, which were selected on the basis of 
quartile distributions. 
The survival analysis was conducted according to the Kaplan-Meier method, and the results were 
compared with the log-rank test. The date of diagnosis used to calculate survival was that of the 
histopathological examination. The multivariate analysis included the values that were statistically 
significant in the univariate analysis (p < 0.05). For numerical values, comparisons were based on the 
median as the threshold value. The multivariate analysis was conducted according to the Cox model. 
All statistical analyses were performed with SPSS statistics v20 (IBM Inc., Armonk, NY, USA). 
6. Results 
6.1. Patient Characteristics 
We identified 44 elderly (age ≥ 70 years) GBM patients who were treated at the Paul Strauss Center 
between 2005 and 2010. Their characteristics are summarized in Table 1.  
Table 1. Patients and treatment characteristics. 
Patient characteristics N % 
Age (years) 
  
70–75 18 41% 
>75 26 59% 
Median 75,5 
 
Gender 
  
Male 26 59% 
Female 18 41% 
Pre Radiotherapy KPS 
  
<70 12 27% 
70–100 31 70% 
undetermined 1 2% 
Median 70 
 
Quality of removal 
  
Biopsy 19 43% 
Partial Resection 14 32% 
Complete Resection 11 25% 
MGMT Status 
  
Methylated 12 27% 
Unmethylated 13 30% 
Unknown 19 43% 
Charlson score   
4 14 31.8% 
5 18 40.9% 
6 5 11.4% 
7 4 9.1% 
8 3 6.8% 
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Table 1. Cont. 
Patient characteristics N % 
RPA (according Scott et al.)   
I 17 38.6% 
II 8 18.2% 
III 10 22.7% 
IV 9 20.5% 
Preradiotherapy Steroid Requirement 
  
Yes 29 66% 
No 15 34% 
Lateralisation 
  
Right 19 43% 
Left 24 55% 
Bilateral 1 2% 
Localisation 
  
One lobe 30 68% 
>1 lobe 14 32% 
Radiotherapy   
Hypofractionated 38 86% 
Standard 6 14% 
Concomitant Chemotherapy   
Temozolomide 34 77% 
Temozolomide + Cilengitide 1 2% 
No 9 21% 
Interruption 7 21% 
Adjuvant Temozolomide   
Yes 22 50% 
1–3 cycles 7 32% 
>3 cycles 15 68% 
No 21 48% 
with Cilengitide 1 2% 
The median patient age was 75.5 years old (range, 70–84 years). Twenty-six patients were older 
than 75 years of age. The median Karnofsky performance status (KPS) was 70% (range, 40–90). The 
Charlson scores were 4 for 14 patients, 5 for 18 patients and 6 or higher for 12 patients. Additionally, 
54% of the patients presented with high blood pressure, and 18% presented with atrial fibrillation. Five 
patients (11%) had a previous history of cancer (one patient with melanoma, one with prostate cancer 
and three with breast cancer). 
Most patients presented with a combination of symptoms, including monoparesia or hemiparesis 
(36%), confusion (23%), behavioral changes (18%), seizures (16%) or vision troubles (18%), 
headaches (14%), memory disturbances (11%), balance troubles (7%), and asthenia (5%). The median 
duration of symptoms prior to the histological diagnosis was 30 days (range, 2–117 days).  
The tumors were localized in the frontal, parietal, temporal, and occipital lobes in 7, 6, 10, and 5 
patients, respectively. In 14 cases, the tumors invaded several lobes. The tumors were localized in the 
right and left hemispheres in 55% and 43% of the cases, respectively. One tumor was bilateral (Table 1). 
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The patients were classified according to their RPA scores, as described by Scott et al. [12]. 
Specifically, 17, 8, 10 and 9 patients received RPA scores of I, II, III and IV, respectively (Table 1). 
6.2. Treatment 
The treatment characteristics are summarized in Table 1. All patients underwent surgery. Nineteen 
patients (43%) only underwent biopsy, and most patients underwent tumor resection; 14 patients 
(32%) underwent subtotal resection and 11 (25%) underwent complete resection. Five patients 
received implanted carmustine wafers. 
All of the patients received radiotherapy. The median delay from histological diagnosis to 
radiotherapy was 43 days (range, 8–232 days). Thirty-eight patients received a prescribed total dose of 
40.5 Gy, given in 15 total 2.7-Gy fractions at a rate of five fractions per week. Six patients received a 
total radiation dose of 60 Gy, given in 30.2-Gy fractions. The median radiotherapy duration was 22 days 
(range, 18–51 days). Two patients who were prescribed hypofractionated treatments died before 
completing radiotherapy and received total doses of 29.5 and 13.5 Gy. Death was considered 
independent of the radiation procedure. 
Concomitant chemotherapy was administered to 35 patients (77%), of whom 34 received daily 
TMZ at a dose of 75 mg/m
2
 and one received TMZ and cilengitide according to a trial protocol. Nine 
patients did not receive any concomitant chemotherapy due to their general conditions. Concomitant 
chemotherapy was interrupted in seven patients due to blood toxicity. 
Among all of the patients, twenty-three (52%) received adjuvant chemotherapy with a 5-day TMZ 
schedule. The average adjuvant TMZ chemotherapy duration was five cycles (range, 1–12). Seven 
patients received 1–3 cycles of chemotherapy, and 16 received more than three cycles. Twenty-one 
patients did not receive adjuvant chemotherapy due to their general conditions or because they died 
prior to treatment. The primary treatments are summarized in Table 1. 
At the time of tumor progression, no patients underwent second surgeries, but 10 received 
additional salvage chemotherapy, which included bevacizumab-irinotecan (n = 7), carboplatine VP16 
(n = 2), and carmustine (n = 1) regimens. 
6.3. Survival and Prognostic Factors 
At the time of this analysis, 41 of the 44 patients had died. The median overall survival (OS) was 
7.2 months. The one- and two-year OS rates were 32% and 12%, respectively. The median 
progression-free survival was 6.7 months (Figure 1). 
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Figure 1. Overall survival for all patients. 
 
In the univariate analyses, the prognostic factors of OS were KPS (<70 versus ≥70; 4.3 versus 10.3 
months; p = 0.0001), concomitant chemotherapy (4 versus 9.8 months; p = 0.0001), and the number of 
adjuvant TMZ cycles (1–3 cycles versus > 3 cycles, none; p = 0.0001). Patient age, gender, the interval 
between surgery and radiotherapy, surgery extension, radiotherapy schedule, the MGMT status, and 
the Charlson score were not prognostic factors. In a multivariable analysis, longer overall survival was 
only associated with KPS (Figure 2). 
Figure 2. Overall survival curves of patients according to Karnofsky performance score (KPS). 
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6.4. Charlson Score and Outcome 
There were no significant differences between the different Charlson score classes. With a cut-off 
of 4, we observed median overall survival values of 11.1 months (range, 9.1–20.8) for patients with 
scores of 4 and 6.9 months (range, 6.8–16.0) for those with scores greater than 4 (p = 0.3). 
7. RPA Score and Outcome 
In an analysis of RPA, the median survival durations for patients with RPA scores of I, II, III and 
IV were 9.5 months, 9.8 months, 6.9 months and 4 months, respectively (p <0.001; Figure 3). 
Figure 3. Overall survival of patients according to RPA score (p < 0.001). (GTR: gross 
total resection; KPS: Karnofsky performance score; PR: partial resection). 
 
7.1. MGMT Methylation and Outcome 
MGMT statuses were available in only 24 patients (57%). The MGMT promoter was methylated in 
12 (27%) patients and unmethylated in 13 (30%) patients. The median OS among patients with 
MGMT methylation was 20.6 months (range, 15.2–26.1), compared with 8.9 months (range, 1.1–16) 
among those without MGMT methylation (p = 0.08). The associated one-year OS rates were 64% and 
38%, respectively (Figure 4). 
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Figure 4. Overall survival curves of patients with methylated or unmethylated MGMT. 
 
7.2. Surgery to Radiotherapy Delay 
In a univariate analysis, there were no significant differences between the four groups that 
corresponded to the quartile distribution of delays (p = 0.21). 
7.3. Toxicity 
TMZ was generally well tolerated. Concomitant or adjuvant TMZ chemotherapy was definitely 
interrupted in six patients. The reasons for interruptions included the following: thrombopenia in two 
cases, cutaneous toxicity in one case, and the patients’ general conditions in three cases. Radiotherapy 
was not interrupted for medical reasons for those patients who remained alive at the end of radiotherapy. 
8. Discussion 
The superiority of radiotherapy, compared to best supportive care, in elderly patients with KPS >70% 
has already been demonstrated in a recent randomized trial [1]. Although our series could be 
considered small in terms of the patient number, we showed an overall survival median comparable to 
that of a larger series published by Scott et al., along with comparable prognostic factors such as the 
KPS and chemotherapy [13]. In another series, Barker et al. found, among other prognostic factors, 
that combined concomitant RT and CT was a favorable prognostic factor of overall survival [14]. After 
analyzing the RTOG RPA, the authors concluded that this classification was marginally effective in 
their series patients. However, in that series, the patients were older than 65 years of age [14]. Other 
series reported some comparable prognostic factors, but did not always include only patients older than 
70 years of age [15,16]. In the largest series of patients older than 70 years of age, Scott et al. 
described a RPA adapted to older patients. This RPA, which was derived from an American series, 
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was implemented in another independent French series with a partial concordance. This RPA remains 
to be tested in prospective trials [12]. In our series, we showed that the difference in OS according to 
RPA was significant. 
Interestingly, two randomized trials showed that hypofractionated radiotherapy schedules to 
administer total doses of 40 Gy in 15 consecutive daily fractions or 34 Gy in 15 consecutive daily 
fractions were well tolerated, with no reductions in survival or quality of life when compared to a 
normofractionated schedule [2,3]. This result supports the idea that age should not be a limiting factor 
in glioblastoma treatment [17].  
In the present study, we retrospectively analyzed 44 GBM patients older than 70 years of age who 
had been mainly treated with hypofractionated radiotherapy, with or without concomitant and adjuvant 
TMZ. The median survival and median progression-free survival were 7.2 months and 6.7 months, 
respectively. The median survival of this study was comparable to that of other series that evaluated 
combined hypofractionated radiochemotherapy and adjuvant TMZ (Table 2). However, in some series, 
the median OS was longer [18–22]. There are multiple explanations for this outcome. The population 
in our series was older than 70 years of age, while many other series determined a cutoff for elderly 
people at 60 or 65 years of age, which could influence survival [14]. Recently, Holdhoff et al. [23] 
highlighted the fact that, for patients less than 70 years of age, the standard of care is the schedule used 
in the EORTC/NCIC trial [24] and neither the Nordic trial nor the NOA-08 included patients in a 
standard arm [3,25]. Moreover, there was no minimum KPS for the purpose of hypofractionated 
radiotherapy in this series of patients, which had a minimum KPS of 40%. For patients with KPS >60, 
the median survival of the patients of our series was 10.3 months, comparable to previous series with 
patients treated with a combined treatment [6,8,14,20,22], and superior to radiotherapy alone [1,3,7,25] 
or TMZ alone series [4,5,26]. 
As demonstrated by the KPS, the MGMT status could help physicians to propose the best treatment 
schedules for elderly patients with GBM. We showed a trend of significant difference in the overall 
survival of patients with a methylated MGMT promoter, compared to those with an unmethylated 
promoter. Previous publications reported comparable results [10,18,21,27]. The Charlson score is also 
a potential prognostic factor and should be included in all analyses of elderly cancer patients, even 
those with glioblastoma, as was demonstrated by Fiorentino et al. [28]. 
With regard to the use of TMZ alone as an initial therapy, the results of other studies show survival 
durations ranging from 6 to 9 months [4,5,26,29,30]. In terms of survival benefit, the recent NOA trial 
showed that a dose-dense TMZ regimen, given in cycles of 1 week on, 1 week off, is not inferior to 
radiotherapy alone when treating elderly patients (older than 65 years) with malignant astrocytoma and 
a KPS of 60 or higher [25]. The Nordic trial concluded that the efficiency of TMZ chemotherapy, 
administered on five consecutive days every 28 days for up to six cycles or until radiological 
progression, was comparable to that of hypofractionated irradiation alone in glioblastoma patients 
older than 60 years of age who had OMS performance statuses of 0 to 2 [3]. Today, conclusions about 
the use of TMZ alone cannot be fully supported. However, based on the evidence-based results of this 
prospective study, standard TMZ chemotherapy and hypofractionated radiotherapy are equivalent 
treatments for elderly patients with high-grade gliomas.  
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Table 2. Results of the literature of elder patients with glioblastoma treated at least with radiotherapy. 
Series 
Type 
of trial 
Number of 
patients 
Median age 
(years) IQR 
Median 
KPS (%) 
IQR 
RT total dose 
dose per 
fraction 
CT 
PFS median (months) 
(IQR) 1-yr PFS (IQR) 
2-yr PFS (IQR) 
Prognostic 
factor of PFS 
OS median 
(months) (IQR) 1-yr 
OS (IQR)/2-yr OS 
(IQR) 
Prognostic 
factors of OS 
Malmström  
et al. [3] 
Phase 
III 
93 
NA 
60–70:51 pts 
>70:42 pts 
NA 
OMS1-
2:78% 
No RT TMZa NA 
NA 
8.3 (7.1–9.5) 
27% (18–36) 
NA 
Classical 
irradiation 
unfavourable 
 98 
NA 
60–70:58 pts 
>70:40 pts 
NA 
OMS1-
2:80% 
34 Gy 
3.4 Gy 
No CT NA 
7.5 (6.5–8.6) 
23% (14–31) 
NA 
 100 
NA 
60–70:59 pts 
>70:41 pts 
NA 
OMS1-
2:72% 
60 Gy 
2 Gy 
No CT NA 
6.0 (5.1–6.8) 
17% (10–24) 
NA 
Wick  
et al. [25] 
Phase 
III 
195 72 (66–84) 70 (20–100) No RT 
TMZ  
One week 
on/one 
week of 
3.3 (3.2–4.1) 
12% (7.9–17.1) 
NA 
MGMT 
Extend of 
resection 
8.6 (7.3–10.2) 
34.4% (27.6–41.4) 
NA 
MGMT 
méthylation 
Extent of 
resection 
173 71 (66–82) 80 (50–100) 
60 Gy 
1.8–2 Gy 
No CT 
4.7 (4.2–5.2) 
9.3% (5.5–14.2) 
NA 
9.6 (8.2–10.8) 
37.4% (30.1–44.7) 
NA 
Roa  
et al. [2] 
Phase 
III 
47 
72.4 ± 5.4 
(SD) £ 
70 
60–80 
60 Gy 
2 Gy 
No CT NA NA 
5.9 
44.7% (6 months) 
NA 
48 
71 ± 5.5 
(SD) £ 
70 
60–80 
40 Gy 
2.67 Gy 
6.1 
41.7% (6 months) 
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Table 2. Cont. 
Series 
Type 
of trial 
Number of 
patients 
Median age 
(years) IQR 
Median 
KPS (%) 
IQR 
RT total dose dose 
per fraction 
CT 
PFS median (months) 
(IQR) 1-yr PFS (IQR) 
2-yr PFS (IQR) 
Prognostic 
factor of PFS 
OS median 
(months) (IQR) 1-yr 
OS (IQR)/2-yr OS 
(IQR) 
Prognostic 
factors of OS 
Keime 
Guibert  
et al. [1]  
Phase 
III 
75 
75 
70–84 
70 
70–100 
50 Gy 
2 Gy 
No 
CT 
14.9 (10.9–22.1)§ 
NA 
NA 
NA 
29.1 (25.4–34.9) § 
NA 
NA 
NA 
73 
73 
70–85 
70 
70–100 
No RT 
No 
CT 
5.4 (4.4–7.6) § 
NA 
NA 
16.9 (13.4–21.4) § 
NA 
NA 
McAleese  
et al. [31] 
Phase 
II 
92 
KPS ≤ 50 
or KPS 50–90 and age 50–
70 
or age ≥ 70 
30 Gy 
5 Gy (3 
fractions/week) 
No 
CT 
NA NA 
5 
12% 
NA 
No factor 
Minniti  
et al.[21] 
Phase 
II 
71 
NA 
70–81 
70 
60–100 
40 Gy 
2.66 Gy 
TMZc 
TMZc 
6 (4.1–8.5) 
20% (9–34) 
5% (1–12) 
 
12.4 (9.9–15) 
58% 
20% 
KPS 
Extent of 
resection 
MGMT 
RTOG RPA 
class 
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Table 2. Cont. 
Series Type of trial 
Number of 
patients 
Median age 
(years) IQR 
Median 
KPS (%) 
IQR 
RT total dose 
dose per 
fraction 
CT 
PFS median (months) 
(IQR) 1-yr PFS (IQR) 2-
yr PFS (IQR) 
Prognostic 
factor of PFS 
OS median 
(months) (IQR) 1-yr 
OS (IQR)/2-yr OS 
(IQR) 
Prognostic 
factors of OS 
Brandes  
et al. 
[18] 
Retrospective 
24 
70 
65–77 
72.5 
60–90 
59.4 Gy 
1.8 Gy 
No 
CT 
5.3 (4.8–7.0) 
8.3 (2.2–31.4) 
NA 
KPS 
TMZa 
11.2 (9.4–13.3) 
31.6 (17.3–57.8) 
4.9 (0.6–30.6) 
KPS 32 
69 
65–74 
80 
60–90 
59.4 Gy 
1.8 Gy 
PCV 
6.9 (5.7–10.6) 
15.6 (6.9–35) 
NA 
12.7 (11.2–18.7) 
56.2 (41.4–76.4) 
6.2 (1.6–23.9) 
23 
68 
60–90 
77 
60–90 
59.4 Gy 
1.8 Gy 
TMZa 
10.7 (8.4–16.4) 
47.4 (30.7–73.4) 
NA 
14.9 (13.3–24.3) 
72.5 (56–94) 
20.0 (7.6–53.2) 
Cao 
et al. [8] 
Retrospective 
57 
70 
60–86 
80 
30–100 
40 Gy 
2.67 Gy 
TMZc 
TMZa 
3.9 (2.9–5.3) 
NA 
NA 
NA 
6.9 (4.5–8.6) 
NA 
NA 
Unfavorable 
factors: 
TMZc 
Limited 
resection 
55 
70 
60–81 
70 
30–100 
40 Gy 
2.67 Gy 
No 
CT 
4.7 (3.2–6.1) 
NA 
NA 
9.3 (5.9–11.8) 
NA 
NA 
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Table 2. Cont. 
Series Type of trial 
Number 
of patients 
Median 
age (years) 
IQR 
Median 
KPS (%) 
IQR 
RT total 
dose dose 
per fraction 
CT 
PFS median 
(months) (IQR) 1-yr 
PFS (IQR) 2-yr PFS 
(IQR) 
Prognostic 
factor of PFS 
OS median 
(months) (IQR) 1-yr 
OS (IQR)/2-yr OS 
(IQR) 
Prognostic 
factors of OS 
Combs  
et al. 
[20] 
Retrospective 43 
67 
65–76 
<70%: 
40% pts 
60 Gy 
2 Gy 
TMZc 
TMZa (5 pts) 
4 (0–59) 
18% 
NA 
NA 
11.0 (2–63) 
48% 
8% 
Extent of 
resection 
RTOG RPA 
class 
Glanz  
et al. 
[30] 
Retrospective 
54 
73.3 
70–91 
67.4 
40–90 
60 Gy 
1.8 Gy 
No CT NA 
NA 
4.1 (0.3–22.5) 
9.3% 
NA 
KPS 
32 
74.5 
70–91 
67.7 
50–90 
No RT TMZa NA 
6.0 (0.7–30) 
11.9% 
NA 
Reyngold  
et al. 
[22] 
Retrospective 31 
66 
32–90 
70–100: 
45% of pts 
35.5–41.4 Gy 
14–15 
fractions 
TMZc 
TMZa 
NA NA 
11.0 (1–20) 
NA 
NA 
NA 
Iwamoto  
et al. 
[15] 
Retrospective 394 
71.9 
65–>80 
<70%: 
24.1% 
RT: 80.7% of 
pts 
TMZc:27.2% of 
pts 
TMZc or 
carmustine: 167 
pts 
NA NA 
8.6 (8–9.4) 
NA 
NA 
Age 
KPS 
Single tumor 
resection 
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Table 2. Cont. 
Series Type of trial 
Number of 
patients 
Median 
age (years) 
IQR 
Median KPS 
(%) IQR 
RT total dose 
dose per 
fraction 
CT 
PFS median 
(months) (IQR) 1-yr 
PFS (IQR) 2-yr PFS 
(IQR) 
Prognostic 
factor of PFS 
OS median 
(months) (IQR) 1-yr 
OS (IQR)/2-yr OS 
(IQR) 
Prognostic 
factors of OS 
Scott  
et al. 
[12] 
Retrospective 702 
75 
70–>83.6 
70 
<70%:31% of 
pts 
RT: 78% of 
pts 
<60 Gy: 54% 
≥60 Gy: 46% 
CT: 35% of 
pts 
NA NA 
3.1 to 9.3 
(1.4–11.2) * 
NA 
RPA $ 
Scott  
et al. 
[13] 
Retrospective 206 
75 
70–90 
<70%:50% of 
pts 
59,7 Gy (3–
70) 
2 Gy 
CT: 
20% of pts 
TMZa 
Carmustine 
carboplatine 
NA NA 
4.5 
NA 
NA 
KPS 
Surgical 
resection 
RT 
Chemotherapy 
Barker  
et al. 
[14] 
Retrospective 291 
71 
65–100 
80 
40–100 
NA 
TMZc:40% 
of pts 
TMZa 
NA NA 
12 
NA 
15% (11–20) 
Age 
RTOG RPA 
Extent of 
surgery 
TMZc 
Minniti 
G. [10] 
Retrospective 32 
73.6 
70–79 
80 
70–100 
60 Gy 
2 Gy 
TMZc 
TMZa 
7 (5–9) 
16% (4–28) 
NA 
NA 
10.6 (8.6–12.6) 
37% (23–50) 
NA 
KPS 
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Table 2. Cont. 
Series Type of trial 
Number of 
patients 
Median age 
(years) IQR 
Median KPS 
(%) IQR 
RT total dose 
dose per 
fraction 
CT 
PFS median 
(months) (IQR) 1-yr 
PFS (IQR) 2-yr PFS 
(IQR) 
Prognostic 
factor of PFS 
OS median 
(months) (IQR) 1-yr 
OS (IQR)/2-yr OS 
(IQR) 
Prognostic 
factors of OS 
Sijben  
et al. [7] 
Retrospective 
19 
67  
64–74 
80 
60–90 
60 Gy 
2 Gy 
CT:19 pts 
TMZa 
TMZc 
6 (1.6–24.7) NA 
8,5 (2–24.7) 
NA 
NA 
Extent of 
resection 
KPS 
TMZa-TMZc 20 
70 
65–82 
70 
50–90 
45 Gy 
2.66 Gy 
No CT 4.1 (1.5–14.2) NA 
5.2 (1.5–14.2) 
NA 
NA 
Bauman  
et al. 
[32] 
Retrospective 29 ≥65 ≤50–100 
30 Gy 
3 Gy 
No CT NA NA 
6 
NA 
NA 
NA 
Villa  
et al. 
[33] 
Retrospective 91 
>70:47% of 
pts 
<70%:52% of 
pts 
RT: 50% of 
pts 
54–66 Gy 
1.8–2 Gy or 
1,5 Gy × 
2/day 
CT:10 pts 
Carmustine 
PCV 
NA NA 
4.5 
NA 
NA  
RT 
Mohan 
et al. 
[34] 
Retrospective 102 
74.5 
70–87 
70.5 
RT: 77 pts 
>55 Gy  
1.8–2 Gy: 58 
pts <40 Gy 
3 Gy:19 pts 
Carmustine 
PCV 
Carboplatine 
NA NA 
5.3 (0.1–36.9) 
NA 
NA 
RT 
RTOG RPA 
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Table 2. Cont. 
Series Type of trial 
Number of 
patients 
Median age 
(years) IQR 
Median 
KPS (%) 
IQR 
RT total dose 
dose per 
fraction 
CT 
PFS median (months) 
(IQR) 1-yr PFS (IQR) 
2-yr PFS (IQR) 
Prognostic 
factor of PFS 
OS median 
(months) (IQR) 1-yr 
OS (IQR)/2-yr OS 
(IQR) 
Prognostic 
factors of OS 
Patwardhan  
et al. [35] 
Retrospective 30 >59 
67.9 ± 2.8 
(SD) 
RT for 15 pts 
48–64 Gy 
2 Gy 
BCNU 
TMZa 
NA NA 
3.2 13–6  
according to 
treatment 
Treatment 
Pierga 
et al. [36] 
Retrospective 30 
73 
70–79 
66 
30–100 
45 Gy 
1.8 Gy 
BCNU 
26 § 
NA 
NA 
NA 
36 (8–70) § 
NA 
NA 
NA 
Hoegler and 
Davey [37] 
Retrospective 22 
73 
70–78 
70.4 
30–90 
37.5 Gy 
2.5 Gy 
No CT NA NA 
8 (4.8–9.6) 
NA 
NA 
KPS 
Present series Retrospective 44 
75.5  
70–84 
70 
40–90 
40.5 Gy 
2,7 Gy 
TMZc 
TMZa 
6.7 (4.3–9.1) 
35% 
9% 
NA 
7.2 (4.4–49.1) 
32% 
12% 
KPS 
TMZa 
BED: Biologically Equivalent Dose; CT: chemotherapy; IQR: Interquartile Range; KPS: Karnovski Performance Status; NA: non available; OS: overall survival; PCV: procarbazine, 
lomustine, vincristine; PFS progressive survival; pts: patients; RT: radiotherapy; SD: standart deviation; TMZa: Temozolomide adjuvant or adjuvant-like (monthly treatment); TMZc: 
temozolomide conconcomitant; *: according to RPA; $: design from the series; £: mean (not median); weeks (not months). 
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Due to its ease of delivery, TMZ alone could be considered useful mainly for patients with the 
worst performance statuses. However, in this population with highly altered general conditions, 
Gallego et al. underlined the feasibility of TMZ alone in elderly patients with KPS < 70. Hematologic 
and cutaneous toxicities were the principal deterrents of this approach [29]. These complications were 
also reported in the NOA-08 trial [25]. While Minniti et al. described similar complications, the 
authors also noted that the most common adverse event was grade 2 or 3 fatigue, which occurred in 
10% of patients during RT and in 17% of patients during adjuvant TMZ chemotherapy. In contrast to 
hematologic toxicity, which is often asymptomatic, fatigue can have a substantial impact on a patient’s 
quality of life [10]. 
Wick et al., who concluded that the major finding of the NOA-08 trial was the strong predictive 
power of the MGMT promoter methylation status for event-free survival, determined another point that 
could facilitate decisions about more relevant treatments. MGMT promoter-methylated tumors responded 
better to TMZ than to radiotherapy, whereas the opposite was true for unmethylated tumors [25]. 
For elderly patients, the quality of life is a major concern in radiation trials, and randomized trials 
have evaluated patients’ quality of life [2,3,5]. These trials showed that radiation therapy was not 
deleterious to the quality of life [1,2], even if patients in the Nordic trial who received TMZ reported a 
better quality of life than those who received radiotherapy [3]. Furthermore, these studies showed that 
there was no quality of life reduction due to the use of high-dose irradiation fractions versus a 
normofractionated schedule [2,3]. However, the effect of the time interval between surgery and the 
beginning of radiotherapy on the quality of life remains uncertain. Longer waiting times can induce 
anxiety in both patients and physicians, who may be concerned about tumor progression before 
initiating treatment. However, some previous large series did not find any differences in the quality of 
life, according to this time interval [38–40]. In this series, we did not find any difference in survival 
with respect to different time intervals. Do et al. found that patients with one or more of the following 
factors were treated earlier than patients without these factors: increased age, biopsy surgery only, and 
lower performance status [39]. This finding could partially explain the lack of differences observed in 
our series. 
The potential toxicity associated with combined chemoradiation in elderly patients leads many 
physicians to choose less aggressive treatments. One of the weaknesses of our study is the insufficient 
data regarding the adverse effects of combined therapy, particularly neurocognitive effects and quality 
of life follow-ups. Many previous retrospective studies did not conduct formal neurocognitive testing. 
Standardized assessment scales of essential domains such as daily living activities, communication, 
cognitive function and memory, depression, and quality of life would provide necessary information 
about the uses of any approach in this patient population. The quantification of such complications 
remains challenging, since modifications in neurocognitive status are known to be often attributed to 
epilepsy, antiepileptic drugs, and disease progression. In a prospective series of elderly patients who 
were treated with a combination therapy, Brandes et al. suggested that the median time to the development 
of neurologic toxicity was 6 months, whereas the time to progression was 9.5 months [18]. 
However, some questions remain unresolved. In particular, what age should be used to define 
someone as elderly? The cut-off age is controversial; Wick et al. regarded patients older than 65 years 
of age as elderly [25], but others have defined elderly people as those older than 70 or 75 years of  
age [28,41]. Another issue regards the heterogeneity of the elderly population. Comorbidity analyses have 
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become much more important and could have predictive roles in survival. Even if we cannot demonstrate 
this hypothesis in our series, the comorbidity status could be a useful way to select elderly patients. 
9. Conclusions 
Our results indicate that a combined treatment regimen is tolerable and has few recorded adverse 
effects. The establishment of prognostic factors for elderly people remains challenging. Ultimately, the 
best treatments could be efficiently proposed according to these factors. 
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